Table of Contents Author Guidelines Submit a Manuscript
International Journal of Vascular Medicine
Volume 2013, Article ID 548764, 7 pages
http://dx.doi.org/10.1155/2013/548764
Clinical Study

Influence of Peripheral Artery Disease and Statin Therapy on Apolipoprotein Profiles

1Reynolds Oklahoma Center on Aging, Donald W. Reynolds Department of Geriatric Medicine, University of Oklahoma Health Sciences Center (OUHSC), Oklahoma City, OK 73117, USA
2Veterans Affairs Medical Center, Oklahoma City, OK 73104, USA
3University of Oklahoma Health Sciences Center, O’Donoghue Research Building, 1122 NE 13th Street, Suite 1200, Oklahoma City, OK 73117, USA
4Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA
5Department of Biostatistics and Epidemiology, OUHSC, Oklahoma City, OK 73117, USA
6Cardiovascular Section, Department of Medicine, OUHSC, Oklahoma City, OK 73117, USA

Received 23 June 2013; Accepted 12 August 2013

Academic Editor: Mark Morasch

Copyright © 2013 Andrew W. Gardner et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Apolipoprotein B is a stronger predictor of myocardial infarction than LDL cholesterol, and it is inversely related to physical activity and modifiable with exercise training. As such, apolipoprotein measures may be of particular relevance for subjects with PAD and claudication. We compared plasma apolipoprotein profiles in 29 subjects with peripheral artery disease (PAD) and intermittent claudication and in 39 control subjects. Furthermore, we compared the plasma apolipoprotein profiles of subjects with PAD either treated ( ) or untreated ( ) with statin medications. For the apolipoprotein subparticle analyses, subjects with PAD had higher age-adjusted Lp-B:C ( ) and lower values of Lp-A-I:A-II ( ) than controls. The PAD group taking statins had lower age-adjusted values for apoB ( ), Lp-A-II:B:C:D:E ( ), Lp-B:E + Lp-B:C:E ( ), Lp-B:C ( ), and Lp-A-I ( ) than the untreated PAD group. Subjects with PAD have impaired apolipoprotein profiles than controls, characterized by Lp-B:C and Lp-A-I:A-II. Furthermore, subjects with PAD on statin medications have a more favorable risk profile, particularly noted in multiple apolipoprotein subparticles. The efficacy of statin therapy to improve cardiovascular risk appears more evident in the apolipoprotein sub-particle profile than in the more traditional lipid profile of subjects with PAD and claudication. This trial is registered with ClinicalTrials.gov NCT00618670.